RDY - Dr. Reddy's Laboratories Limited
| Previous Close | 37.69 |
| Open | 38.09 |
| Bid | 35.35 x 1000 |
| Ask | 38.31 x 900 |
| Day's Range | 38.09 - 38.56 |
| 52 Week Range | 28.49 - 42.82 |
| Volume | 83,787 |
| Avg. Volume | 162,661 |
| Market Cap | 6.411B |
| Beta (3Y Monthly) | -0.12 |
| PE Ratio (TTM) | 27.18 |
| EPS (TTM) | 1.40 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.29 (0.70%) |
| Ex-Dividend Date | 2018-07-13 |
| 1y Target Est | 28.03 |
- Zacks•5 days ago
New Strong Sell Stocks for May 22nd
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today:
- Zacks•6 days ago
Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
- InvestorPlace•9 days ago
Dr. Reddy’s Laboratories Earnings: RDY Stock Dips Despite Q4 Beat
Dr. Reddy's Laboratories (NYSE:RDY) reported its quarterly earnings figures on Friday, bringing in a profit that increased year-over-year and revenue that came in ahead of what Wall Street projected in its consensus guidance, yet RDY stock took a step back.The India-based business announced that for its fourth quarter of its fiscal 2019, it raked in earnings of 38 cents per ADS, which was roughly 12 cents higher than the company's profit from the same period in its fiscal 2018. Its revenue also impressed, coming in at $581 million for the three-month period.This amount was 13.7% higher than it was during the year-ago quarter for Dr. Reddy's, while also topping the Zacks Investment Research, which foresaw the company raking in sales of $565.45 million. Revenue from the company's Global Generics segment was up 9% year-over-year, while the Pharmaceutical Services and Active Ingredients segment saw sales surge 8% year-over-year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDr. Reddy's added that its Proprietary Products segment gained 139% year-over-year. For the fiscal year, the company brought in sales of $2.2 billion, gaining 8.3% when compared to the year-ago quarter.Earnings for its fiscal 2019 tallied up to $1.64 per ADS, marking a whopping gain of 92.9% when compared to the year-ago quarter.RDY stock is down about 1.6% on Friday despite the company unveiling quarterly earnings results that came in ahead of what Wall Street called for in its consensus estimate. Shares had been gaining 0.2% during pre-market trading. More From InvestorPlace * 7 Stocks to Buy that Lost 10% Last Week * 6 Chinese Stocks That Could Pop On a Trade Deal * 10 Retirement Stocks That Won't Wilt in a Bear Market Compare Brokers The post Dr. Reddy's Laboratories Earnings: RDY Stock Dips Despite Q4 Beat appeared first on InvestorPlace.
- Business Wire•9 days ago
Dr. Reddy’s Q4 & FY19 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards .
- Zacks•10 days ago
Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat
Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.
- Business Wire•12 days ago
Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin® for Injection, approved by the U.S.
- Zacks•13 days ago
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.
- Business Wire•21 days ago
Dr. Reddy's Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® 1.62%, approved by the U.S.
- PR Newswire•25 days ago
URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders or Former Shareholders To Contact the Firm Immediately
NEW YORK , May 1, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City ...
- Insider Monkey•last month
Here’s What Hedge Funds Think About Dr. Reddy’s Laboratories Limited (RDY)
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]
- Business Wire•last month
Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019
Earnings call slated for May 17, 6:00 PM IST / 8:30 AM EDT
- Zacks•last month
Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
- Business Wire•last month
Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio
Dr. Reddy’s Laboratories Ltd. announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications in the U.S.
- Benzinga•2 months ago
The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
- Benzinga•2 months ago
Is India's 7.3% Growth Worth An Investment?
With economic growth slowing worldwide in 2019, investors looking for growth sources have been forced to get creative. Ongoing concerns about the outcome of the Sino-American trade war have clouded the outlook for the Chinese market, but India has the sixth-largest economy in the world and is expected to grow by 7.3 percent this year, according to the International Monetary Fund. Unreliable Numbers? Unfortunately for India investors, growth projections are dropping worldwide — and India may be no exception.
- Business Wire•2 months ago
Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddy’s Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology
Dr. Reddy’s Laboratories Limited , through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO® Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB® Topical Cream and TRIANEX® 0.05% in the United States, to Encore Dermatology.
- Zacks•2 months ago
Supernus' ADHD Candidate Positive in 4th Phase III Study
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
- Zacks•2 months ago
Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)
Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- Business Wire•2 months ago
Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. , along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis Tablets in the United States market, approved by the U.S.
- Zacks•2 months ago
Top Ranked Momentum Stocks to Buy for March 20th
Top Ranked Momentum Stocks to Buy for March 20th
- GlobeNewswire•3 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within Vanda Pharmaceuticals, Range Resources, Fortune Brands Home & Security, Dr. Reddy's Laboratories, BWX Technologies, and K12 — New Research Emphasizes Economic Growth
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Investopedia•3 months ago
Watching for Signs of Global Risk Events
Investors seem encouraged by Brexit news, but hostilities are escalating between India and Pakistan. GDP is on deck.
- Business Wire•3 months ago
Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation
Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the re-launch of its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone® sublingual film, in the United States market.
- Zacks•4 months ago
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3
Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.
